<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00750139</url>
  </required_header>
  <id_info>
    <org_study_id>MUS 90200-0736/1</org_study_id>
    <nct_id>NCT00750139</nct_id>
  </id_info>
  <brief_title>Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis</brief_title>
  <official_title>A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-500 in Subjects With Tinea Pedis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merz North America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merz North America, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A research study to compare the safety and effectiveness of an investigational medication
      called NAFT-500 to placebo, when used in subjects with tinea pedis (athlete's foot).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the efficacy and safety of NAFT-500 compared to placebo in the treatment of
      subjects with potassium hydroxide (KOH) and culture positive symptomatic tinea pedis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects With Complete Cure at Week 6.</measure>
    <time_frame>Week 6</time_frame>
    <description>The first primary efficacy variable was the percentage of subjects in the NAFT-500 Cream, 2% or 2-week placebo groups with complete cure at Week 6.
The second primary efficacy variable was the percentage of subjects in the Naftin 1% Cream or 4-week placebo groups with complete cure at Week 6.
Complete cure was defined as negative mycology results from the central laboratory (dermatophyte culture and KOH) and absence of erythema, scaling, and pruritus that were evaluated using a 4 point severity scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Mycological Cure and Percentage of Subjects With Treatment Effectiveness at Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>Mycological Cure was defined as negative KOH result and negative dermatophyte culture at Week 6. Treatment Effectiveness was defined as negative KOH, negative culture, and Scaling, Erythema, and Pruritus grades of 0 or 1 at Week 6.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">707</enrollment>
  <condition>Tinea Pedis</condition>
  <condition>Athlete's Foot</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naftin 2% cream applied daily for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo cream applied daily for two weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active comparator applied daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo cream applied daily for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NAFT-500</intervention_name>
    <description>topical cream 1 application every day up to 4 weeks weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 2-weeks</intervention_name>
    <description>placebo cream 1 application every day for up to 4 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naftin 1%</intervention_name>
    <description>topical allylamine cream applied once a day for up to 4 weeks</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 4-weeks</intervention_name>
    <description>topical placebo cream applied once a day for up to 4 weeks</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Review and sign a statement of Informed Consent and HIPAA authorization.

          2. For minors (less than 18 years), the parent/legal guardian must complete the informed
             consent process AND the subject must complete the assent process and sign the
             appropriate form (if age appropriate).

          3. Males or non-pregnant females â‰¥12 years of age, of any race or sex. Females of
             childbearing potential must have a negative urine pregnancy test.

          4. Presence of tinea pedis on one or both feet characterized by clinical evidence of a
             tinea infection (at least moderate erythema, moderate scaling, and mild pruritus)based
             on signs and symptoms.

          5. KOH positive and culture positive baseline skin scrapings obtained from the site most
             severely affected or a representative site of the overall severity.

          6. Subjects must be in good health and free from any clinically significant disease that
             might interfere with the study evaluations.

          7. Subject must be able to understand the requirements of the study and willing to comply
             with the study requirements.

        Exclusion Criteria:

          1. A life-threatening condition (ex. autoimmune deficiency syndrome, cancer, unstable
             angina, or myocardial infarction) within the last 6 months.

          2. Subjects with abnormal findings - physical or laboratory - that are considered by the
             investigator to be clinically important and indicative of conditions that might
             complicate interpretation of study results.

          3. Subjects with a known hypersensitivity to study medications or their components.

          4. Subjects who have a recent history or who are currently known to abuse alcohol or
             drugs.

          5. Uncontrolled diabetes mellitus.

          6. Hemodialysis or chronic ambulatory peritoneal dialysis therapy.

          7. Current diagnosis of immunocompromising conditions.

          8. Foot psoriasis, corns and/or callus involving any web spaces, atopic or contact
             dermatitis.

          9. Severe dermatophytoses, onychomycosis (on the evaluated foot), mucocutaneous
             candidiasis, or bacterial skin infection.

         10. Extremely severe tinea pedis (incapacitating).

         11. Female subject who is pregnant or lactating, who is not using or does not agree to use
             an acceptable form of contraception during the study, or who intends to become
             pregnant during the study (females who are surgically sterilized or post menopausal
             for at least 2 years are not considered to be of childbearing potential).For the
             purposes of this study, acceptable forms of birth control include: oral
             contraceptives, contraceptive patches/implants, double barrier methods (e.g., use of
             condom and spermicide), IUD, and abstinence with second acceptable method should
             subject become sexually active.

         12. Subjects using the following medications:

               -  Topical anti-fungal therapy, foot/shoe powders, or topical corticosteroids
                  applied to the feet within 14 days prior to randomization. Topical terbinafine,
                  butenafine,and naftifine within 30 days prior to randomization

               -  Oral anti-fungal therapies 3 months (8 months for oral terbinafine) prior to
                  randomization

               -  Systemic antibiotic or corticosteroid treatment within 30 days of randomization

               -  Any other significant treatments, except hormonal contraception and multivitamin,
                  at the discretion of the investigator that would interfere with study treatment.

               -  Investigational drug within 30 days of randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence Parish, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Paddington Testing Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Felix Sigal</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90010-3209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco, Dept of Dermatology</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FXM Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FXM Research</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glazer Dermatology</name>
      <address>
        <city>Buffalo Grove</city>
        <state>Illinois</state>
        <zip>60089</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University Health Services</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Silverton Skin Institute</name>
      <address>
        <city>Grand Blanc</city>
        <state>Michigan</state>
        <zip>48439</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zoe Draelos, MD</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haber Dermatology</name>
      <address>
        <city>Euclid</city>
        <state>Ohio</state>
        <zip>44118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Dermatology and Research Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paddington Testing Company</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University School of Podiatric Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center</name>
      <address>
        <city>Mt. Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J &amp; S Studies</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Across America</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Across America</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2008</study_first_submitted>
  <study_first_submitted_qc>September 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2008</study_first_posted>
  <results_first_submitted>February 13, 2012</results_first_submitted>
  <results_first_submitted_qc>December 18, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 29, 2013</results_first_posted>
  <disposition_first_submitted>June 14, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>July 11, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 14, 2011</disposition_first_posted>
  <last_update_submitted>April 19, 2013</last_update_submitted>
  <last_update_submitted_qc>April 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tinea Pedis</keyword>
  <keyword>Athlete's foot</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinea</mesh_term>
    <mesh_term>Tinea Pedis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>NAFT-500</title>
          <description>Naftin 2% Cream applied daily for 2 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo 2-wks</title>
          <description>Placebo applied daily for 2-weeks</description>
        </group>
        <group group_id="P3">
          <title>Naftin 1%</title>
          <description>Naftin 1% active comparator applied daily for 4 weeks</description>
        </group>
        <group group_id="P4">
          <title>Placebo 4-wks</title>
          <description>Placebo cream applied daily for 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="234"/>
                <participants group_id="P2" count="118"/>
                <participants group_id="P3" count="236"/>
                <participants group_id="P4" count="119"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="145"/>
                <participants group_id="P2" count="59"/>
                <participants group_id="P3" count="135"/>
                <participants group_id="P4" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="59"/>
                <participants group_id="P3" count="101"/>
                <participants group_id="P4" count="46"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Termination by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-specific</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="79"/>
                <participants group_id="P4" count="33"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>NAFT-500</title>
          <description>Naftin 2% Cream applied daily for 2 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo 2-wks</title>
          <description>Placebo applied daily for 2-weeks</description>
        </group>
        <group group_id="B3">
          <title>Naftin 1%</title>
          <description>Naftin 1% active comparator applied daily for 4 weeks</description>
        </group>
        <group group_id="B4">
          <title>Placebo 4-wks</title>
          <description>Placebo cream applied daily for 4 weeks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="234"/>
            <count group_id="B2" value="118"/>
            <count group_id="B3" value="236"/>
            <count group_id="B4" value="119"/>
            <count group_id="B5" value="707"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="220"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="212"/>
                    <measurement group_id="B4" value="111"/>
                    <measurement group_id="B5" value="658"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.7" spread="13.03"/>
                    <measurement group_id="B2" value="41.0" spread="12.91"/>
                    <measurement group_id="B3" value="41.4" spread="14.08"/>
                    <measurement group_id="B4" value="41.4" spread="14.00"/>
                    <measurement group_id="B5" value="41.7" spread="13.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="165"/>
                    <measurement group_id="B4" value="86"/>
                    <measurement group_id="B5" value="502"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="234"/>
                    <measurement group_id="B2" value="118"/>
                    <measurement group_id="B3" value="236"/>
                    <measurement group_id="B4" value="119"/>
                    <measurement group_id="B5" value="707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With Complete Cure at Week 6.</title>
        <description>The first primary efficacy variable was the percentage of subjects in the NAFT-500 Cream, 2% or 2-week placebo groups with complete cure at Week 6.
The second primary efficacy variable was the percentage of subjects in the Naftin 1% Cream or 4-week placebo groups with complete cure at Week 6.
Complete cure was defined as negative mycology results from the central laboratory (dermatophyte culture and KOH) and absence of erythema, scaling, and pruritus that were evaluated using a 4 point severity scale.</description>
        <time_frame>Week 6</time_frame>
        <population>This is based on the Full Analysis Set (FAS). The FAS is the subset of all subjects in the Safety Evaluation Set (SES) with a positive culture at baseline for whom the primary efficacy variable is available. This is a modified intent to treat (MITT) principle because the culture results will not be available before the start of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>NAFT-500</title>
            <description>Naftin 2% Cream applied daily for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo 2-weeks</title>
            <description>Placebo Control cream applied daily for 2-weeks</description>
          </group>
          <group group_id="O3">
            <title>Naftin 1%</title>
            <description>Naftin 1% active comparator applied daily for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo 4-wks</title>
            <description>Placebo control cream applied daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Complete Cure at Week 6.</title>
          <description>The first primary efficacy variable was the percentage of subjects in the NAFT-500 Cream, 2% or 2-week placebo groups with complete cure at Week 6.
The second primary efficacy variable was the percentage of subjects in the Naftin 1% Cream or 4-week placebo groups with complete cure at Week 6.
Complete cure was defined as negative mycology results from the central laboratory (dermatophyte culture and KOH) and absence of erythema, scaling, and pruritus that were evaluated using a 4 point severity scale.</description>
          <population>This is based on the Full Analysis Set (FAS). The FAS is the subset of all subjects in the Safety Evaluation Set (SES) with a positive culture at baseline for whom the primary efficacy variable is available. This is a modified intent to treat (MITT) principle because the culture results will not be available before the start of treatment.</population>
          <units>percentage of subjects with complete cur</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="143"/>
                <count group_id="O4" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7"/>
                    <measurement group_id="O2" value="7.1"/>
                    <measurement group_id="O3" value="16.1"/>
                    <measurement group_id="O4" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The first primary efficacy hypotheses tests are:
H01: p1 â‰¤ p01 vs. H1: p1 &gt; p01 where p01 and p1 denote the proportions of complete cure in the placebo 2wks and NAFT-500 groups, respectively.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <p_value_desc>The first primary efficacy analyses will use the Cochran-Mantel-Haenszel (CMH) test after stratification by pooled clinical site. The test will be conducted with the FAS at a one-sided level of significance of Î± = 0.025.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The second primary efficacy hypotheses tests are:
H02: p2 â‰¤ P02 vs. H2: P2 &gt; p02 where p02 and p2 are denote proportions of complete cure in the placebo 4wks and Naftin 1% groups, respectively</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>The second primary efficacy analyses will use the Cochran-Mantel-Haenszel (CMH) test after stratification by pooled clinical site. The test will be conducted with the FAS at a one-sided level of significance of Î± = 0.025</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Mycological Cure and Percentage of Subjects With Treatment Effectiveness at Week 6</title>
        <description>Mycological Cure was defined as negative KOH result and negative dermatophyte culture at Week 6. Treatment Effectiveness was defined as negative KOH, negative culture, and Scaling, Erythema, and Pruritus grades of 0 or 1 at Week 6.</description>
        <time_frame>Week 6</time_frame>
        <population>This was the Full Analysis Set (FAS) comprising of subjects in the Safety Evaluation Set (SES) with a positive culture at baseline for whom the primary efficacy variable was available. This was a Modified Intent to Treat (MITT) principle because the culture results were not available at the start of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>NAFT-500</title>
            <description>Naftin 2% Cream applied daily for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo 2-wks</title>
            <description>Placebo applied daily for 2-weeks</description>
          </group>
          <group group_id="O3">
            <title>Naftin 1%</title>
            <description>Naftin 1% active comparator applied daily for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo 4-wks</title>
            <description>Placebo cream applied daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Mycological Cure and Percentage of Subjects With Treatment Effectiveness at Week 6</title>
          <description>Mycological Cure was defined as negative KOH result and negative dermatophyte culture at Week 6. Treatment Effectiveness was defined as negative KOH, negative culture, and Scaling, Erythema, and Pruritus grades of 0 or 1 at Week 6.</description>
          <population>This was the Full Analysis Set (FAS) comprising of subjects in the Safety Evaluation Set (SES) with a positive culture at baseline for whom the primary efficacy variable was available. This was a Modified Intent to Treat (MITT) principle because the culture results were not available at the start of treatment.</population>
          <units>percentage of Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="143"/>
                <count group_id="O4" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mycological Cure (MC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.3"/>
                    <measurement group_id="O2" value="21.4"/>
                    <measurement group_id="O3" value="71.3"/>
                    <measurement group_id="O4" value="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Effectiveness (TE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.5"/>
                    <measurement group_id="O2" value="20.0"/>
                    <measurement group_id="O3" value="58.7"/>
                    <measurement group_id="O4" value="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>NAFT-500</title>
          <description>Naftin 2% Cream applied daily for 2 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo 2-wks</title>
          <description>Placebo applied daily for 2-weeks</description>
        </group>
        <group group_id="E3">
          <title>Naftin 1%</title>
          <description>Naftin 1% active comparator applied daily for 4 weeks</description>
        </group>
        <group group_id="E4">
          <title>Placebo 4-wks</title>
          <description>Placebo cream applied daily for 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application Site Irritation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Application Site Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Application Site Dryness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Blood Glucose Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Protein Urine Present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Institution and Principal Investigator agree not to individually publish the results of the Study. Institution and Principal Investigator may, however, upon written notice to Merz participate in a joint, multicenter publication of the Study results with other investigators and/or institutions, provided that the manuscript or abstract is first reviewed by Merz.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Associate Medical Director- Dermatology</name_or_title>
      <organization>Merz Pharmaceuticals, LLC</organization>
      <phone>800-334-0514</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

